Tianjin Medical Journal

Tianjin Medical Journal ›› 2021, Vol. 49 ›› Issue (4): 436-440.doi: 10.11958/20202963

• Drug Clinical Evaluations • Previous Articles     Next Articles

The clinical efficacy and safety of anlotinib combined with irinotecan as the second-line therapy in patients with small cell lung cancer

LYU Yi-hua1, ZHAO Zi-long2, HUANG Ge-hong1, BA Ya-er1, DU Wei1, GAO Hui1, ZHANG Mei-yun1△   

  1. 1 Department of General Oncology, Baotou Tumor Hospital, Baotou 014030, China; 2 Department of Respiratory Medicine, the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
  • Received:2020-10-27 Revised:2020-12-27 Published:2021-04-15 Online:2021-04-16
  • Contact: ZHANG Mei-yun E-mail:zmy_130@sina.com

PDF (PC)

4654

Abstract: Objective　To observe the clinical efficacy and safety of anlotinib combined with irinotecan in the second-line treatment of small cell lung cancer (SCLC). Methods　A total of 82 SCLC patients who failed at the first-line treatment were selected as the research objects, and they were randomly divided into control group (41 cases) and study group (41 cases) according to the random number table method. The control group was treated with irinotecan, and the study group was treated with anlotinib on the basis of the control group for six courses. The disease control rate (DCR), objective remission rate (ORR), overall survival time (OS), progression free survival time (PFS) and adverse reactions were observed. The serum vascular endothelial growth factor (VEGF), pleiotropic protein (PTN) and soluble death receptor 5 (sDR5) levels were detected by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Results　The ORR (53.66% vs. 31.71%, χ2=4.038) and DCR (87.80% vs. 68.29%, χ2=4.556) were significantly higher in the study group than those of the control group (P＜0.05). The median PFS in the study group was longer than that in the control group (5 months vs. 3 months, Log-rank χ2=7.752, P＜0.01), and the median OS difference was not statistically significant (9 months vs. 7 months, Log-rank χ2=3.701, P＞0.05). After treatment, the serum levels of VEGF, PTN and sDR5 were significantly lower than those of before treatment in the two groups (P＜0.05), and the levels of VEGF, PTN and sDR5 were significantly lower in the study group than those of in the control group (P＜0.05). During the treatment, there were no significant differences in the incidence of blood system, digestive system and fatigue of grade Ⅲ and above adverse reactions between the two groups (P＞0.05). Conclusion　Anlotinib combined with irinotecan as the second-line treatment for SCLC has good curative effect, can effectively reduce the serum expressions of VEGF, PTN and sDR5, and has good safety.

Key words: small cell lung carcinoma, molecular targeted therapy, second line treatment, anlotinib, irinotecan, clinical efficacy

CLC Number: